The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)

NCT06699836 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: 350 mg leronlimab
DRUG: 700 mg leronlimab

Sponsor

CytoDyn, Inc.

Collaborators

[object Object]